(2020). Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Ann Intern Med, 173, 417-425. http://doi.org/10.7326/m20-0289.
(2023). Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP-4 inhibitors: population-based cohort study. Clin Pharmacol Ther. http://doi.org/10.1002/cpt.2975.
(2023). Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.15000.
(2022). Common vaccines and the risk of incident dementia: a population-based cohort study. J Infect Dis. http://doi.org/10.1093/infdis/jiac484.
(2022). Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1584.
(2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094.
(2022). 5-α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15317.
(2017). Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. http://doi.org/10.2337/dc17-0595.
(2018). Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k2693.
(2018). Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000000891.